InvestSMART

Xpon Technologies Group Limited (ASX:XPN)

ALERT: Price-sensitive ASX Announcement for XPN
Current share price for XPN : $0.010 0 (0%)+
Release
28 Oct 2025 8:31AM
Price at Release
$0.010
Full Release
download
Summary
XPON Technologies Group Limited announced a robust performance in Q1 FY26, achieving a positive operating cash flow of $0.99 million and EBITDA of $0.12 million. The company's revenue grew by 17.5% quarter-on-quarter, largely due to the acquisition of Alpha Digital. Recurring sales revenue constituted 94% of the total, with a stable gross margin of 68%. XPON onboarded 12 new customers and retained 97.5% of their existing customer base. The company also focused on strategic priorities such as enhancing AI capabilities and maintaining financial stability, supported by capital management initiatives that included a successful share placement and a loan agreement.
Key Points
  • XPON Technologies Group Limited reported a strong Q1 FY26 with a positive operating cash flow of $0.99 million.
  • The company's EBITDA was $0.12 million, reflecting strong financial performance.
  • XPON's revenue increased by 17.5% quarter-on-quarter to $3.2 million, driven by the acquisition of Alpha Digital.
  • Recurring sales revenue was $2.98 million, making up 94% of the quarter's total revenue.
  • The gross margin remained stable at 68%.
  • XPON successfully acquired 12 new customers and expanded relationships with 16 existing ones.
  • The company maintained a high customer retention rate of 97.5%.
  • XPON raised $0.45 million in capital and secured a $0.4 million loan, maintaining a cash balance of $2.7 million.
  • Leadership changes included Matt Forman stepping down as CEO and transitioning to a Non-Executive Director role.
  • Strategic priorities for XPON include optimizing their sales strategy, enhancing AI innovation, and sustaining financial stability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.